<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">J Cancer</journal-id><journal-id journal-id-type="publisher-id">jca</journal-id><journal-title-group><journal-title>Journal of Cancer</journal-title></journal-title-group><issn pub-type="epub">1837-9664</issn><publisher><publisher-name>Ivyspring International Publisher</publisher-name><publisher-loc>Sydney</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11786028</article-id><article-id pub-id-type="doi">10.7150/jca.105173</article-id><article-id pub-id-type="publisher-id">jcav16p1118</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>CT Urography-Based Radiomics to Predict ISUP Grading of Clear Cell Renal Cell Carcinoma</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jiao</surname><given-names>Panpan</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A3" ref-type="aff">3</xref><xref rid="FNA_number" ref-type="author-notes">#</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Bin</given-names></name><xref rid="A2" ref-type="aff">2</xref><xref rid="FNA_number" ref-type="author-notes">#</xref></contrib><contrib contrib-type="author"><name><surname>Ni</surname><given-names>Xinmiao</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A3" ref-type="aff">3</xref><xref rid="FNA_number" ref-type="author-notes">#</xref></contrib><contrib contrib-type="author"><name><surname>Lu</surname><given-names>Yi</given-names></name><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Rui</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Yunxun</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Jingsong</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Mei</surname><given-names>Haonan</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Xiuheng</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Weng</surname><given-names>Xiaodong</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A3" ref-type="aff">3</xref><xref rid="FNA_envelop" ref-type="corresp">&#x02709;</xref></contrib><contrib contrib-type="author"><name><surname>Zheng</surname><given-names>Qingyuan</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A3" ref-type="aff">3</xref><xref rid="FNA_envelop" ref-type="corresp">&#x02709;</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Zhiyuan</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A3" ref-type="aff">3</xref><xref rid="FNA_envelop" ref-type="corresp">&#x02709;</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, China.</aff><aff id="A2"><label>2</label>Department of Urology, Suizhou Central Hospital, Suizhou, Hubei, 441300, China.</aff><aff id="A3"><label>3</label>Institute of Urologic Disease, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, China.</aff><aff id="A4"><label>4</label>Department of Ophthalmology, Renmin Hospital of Wuhan University, Wuhan, China.</aff><author-notes><corresp id="FNA_envelop">&#x02709; Corresponding authors: Xiaodong Weng, Qingyuan Zheng and Zhiyuan Chen. Tel.: +86 027 88041911. E-mail: <email>wengxdx@163.com</email> (Xiaodong Weng), <email>zqy710890394@whu.edu.cn</email> (Qingyuan Zheng) and <email>drchenzy@whu.edu.cn</email> (Zhiyuan Chen).</corresp><fn fn-type="equal" id="FNA_number"><p># These authors contributed equally to this work.</p></fn><fn fn-type="COI-statement"><p>Competing Interests: The authors have declared that no competing interest exists.</p></fn></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>6</day><month>1</month><year>2025</year></pub-date><volume>16</volume><issue>4</issue><fpage>1118</fpage><lpage>1126</lpage><history><date date-type="received"><day>14</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>17</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The author(s)</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>). See <ext-link ext-link-type="uri" xlink:href="https://ivyspring.com/terms">https://ivyspring.com/terms</ext-link> for full terms and conditions.</license-p></license></permissions><abstract><p><bold>Purpose:</bold> Exploring the value of predicting the WHO/ISUP grade of clear cell renal cell carcinoma (ccRCC) using computed tomography urography (CTU) images, providing valuable recommendations for the treatment of ccRCC.</p><p><bold>Method:</bold> CTU images from the Renmin Hospital of Wuhan University (RHWU) cohort, including 328 patients with ccRCC, were retrospectively collected. The corticomedullary (CMP) phase features of ccRCC were extracted from the CTU images using the Pyradiomics package, and key features were selected through the Least Absolute Shrinkage and Selection Operator (LASSO) regression. The 328 patients were split into training and testing sets in a 7:3 ratio. 175 patients from the The Cancer Genome Atlas (TCGA) cohort were used for the external validation set. Various models, including Logistic Regression (LR), Multilayer Perceptron (MLP), Support Vector Machine (SVM), and eXtreme Gradient Boosting (XGBoost), were employed to predict the ISUP grade. SHAP analysis was then used to visualize the performance of the best model.</p><p><bold>Results:</bold> A total of 1,218 features were extracted using the Pyradiomics package, with 20 features selected for model training through LASSO analysis. In the training set, the AUC for the LR model was 0.88 (95% confidence interval [CI] 0.84-0.91), for MLP it was 0.89 (95% CI 0.86-0.93), for SVM it was 0.86 (95% CI 0.83-0.90), and for XGBoost it was 0.96 (95% CI 0.92-0.99). In the testing set, the AUC for LR was 0.79 (95% CI 0.73-0.85), for MLP it was 0.78 (95% CI 0.72-0.83), for SVM it was 0.78 (95% CI 0.73-0.82), and for XGBoost it was 0.80 (95% CI 0.75-0.85). In the validation set, the AUC for LR was 0.74 (95% CI 0.68-0.79), for MLP it was 0.68 (95% CI 0.63-0.73), for SVM it was 0.67 (95% CI 0.64-0.71), and for XGBoost it was 0.78 (95% CI 0.74-0.83). XGBoost demonstrated superior performance, with a sensitivity of 0.99 (95% CI 0.96-1.00) in the training set, 0.92 (95% CI 0.88-0.97) in the testing set and 0.91 (95% CI 0.86,0.95) in validation set. SHAP analysis revealed that the wavelet-LHL_glcm_Idn and wavelet-LHL_glrlm_LongRunEmphasis features played pivotal roles in the classification task.</p><p><bold>Conclusion:</bold> In this study, we employ an artificial intelligence model to conduct non-invasive ISUP grade prediction on preoperative CTU images of ccRCC, thereby aiding clinical decision-making. Additionally, we uncover that the radiomics features extracted from the CMP phase of CTU images hold promise as potential biomarkers for grading ccRCC.</p></abstract><kwd-group><kwd>Clear cell renal cell carcinoma</kwd><kwd>ISUP grading</kwd><kwd>Radiomics</kwd><kwd>Machine learning</kwd><kwd>Artificial intelligence</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Renal cell carcinoma is a common tumor originating from renal tubular epithelial cells<xref rid="B1" ref-type="bibr">1</xref>. In 2020, approximately 431,000 new cases of renal cancer were reported globally, with 271,000 occurring in men<xref rid="B2" ref-type="bibr">2</xref>. Studies indicate that the global incidence of renal cancer continues to rise<xref rid="B3" ref-type="bibr">3</xref>. Clear cell renal cell carcinoma (ccRCC) is the most prevalent type, accounting for around 70% of all renal cancers<xref rid="B4" ref-type="bibr">4</xref>. The diagnosis of ccRCC primarily relies on traditional histopathological examination. Evidence suggests that morphological changes in the nucleolus can be observed in cancerous tissues, indicating a diagnosis, and the relationship between nucleolar hypertrophy and poor prognosis has drawn increasing attention from pathologists<xref rid="B5" ref-type="bibr">5</xref>. Numerous studies have identified nucleolar hypertrophy as a prognostic indicator of poor outcomes in cancer patients<xref rid="B6" ref-type="bibr">6</xref>. Additionally, nuclear morphological characteristics can help distinguish low-grade from high-grade tumors, with nuclear atypia often linked to malignancy<xref rid="B7" ref-type="bibr">7</xref>.</p><p>The grading system was introduced by the International Society of Urological Pathology (ISUP) at the Vancouver meeting in 2012 and is recommended for use by the World Health Organization (WHO). The degree of nucleolar prominence is assessed to determine grades 1 to 3, while the presence of highly atypical pleomorphic cells and/or sarcomatoid or rhabdomyomatous morphology indicates grade 4<xref rid="B8" ref-type="bibr">8</xref>. In comparison to the Fuhrman system, the ISUP grading system may place greater emphasis on evaluating tumor necrosis and sarcomatoid and rhabdomyomatous features, which are not adequately represented in the Fuhrman system<xref rid="B9" ref-type="bibr">9</xref>. The ISUP grading system is easier to apply and demonstrates greater reproducibility and clinical relevance<xref rid="B10" ref-type="bibr">10</xref>. Percutaneous pathological biopsy is a common method for preoperative grading of ccRCC but often results in bleeding. Furthermore, due to the heterogeneity of ccRCC, inconsistencies can occur between biopsy and resection samples within the ISUP grading system. Thus, there is an urgent need to develop a new, non-invasive, and effective method for determining the histological grade of ccRCC.</p><p>In recent years, numerous studies have explored the intersection of artificial intelligence technology and ccRCC. Yeh, F.C. <italic>et al.</italic> achieved segmentation and classification of nuclei in pathological images<xref rid="B11" ref-type="bibr">11</xref>. Pan, L. <italic>et al.</italic> utilized multimodal MRI radiomics to predict the Fuhrman grading of ccRCC<xref rid="B12" ref-type="bibr">12</xref>. Zhang, Y. <italic>et al.</italic> developed a multi-information fusion model that integrates tumor CT features and biochemical indicators to predict the Fuhrman grading of ccRCC<xref rid="B13" ref-type="bibr">13</xref>.</p><p>However, there have been no large-scale cohort studies investigating the ISUP grading of ccRCC. In this study, we aimed to utilize radiomics and machine learning techniques to predict the ISUP grading of ccRCC, providing a non-invasive method for determining the ISUP grade. This approach might facilitate improved clinical management and enhance patient prognosis.</p></sec><sec sec-type="methods"><title>Methods</title><p>The design process of the entire study is illustrated in <bold>Figure <xref rid="F1" ref-type="fig">1</xref></bold>.</p><sec><title>Study population</title><p>This study adhered to the Helsinki Declaration and received approval from the Clinical Research Ethics Committee of Renmin Hospital of Wuhan University (RHWU), with approval number WDRY2022-K077. We recruited 700 patients who underwent surgery for ccRCC at RHWU between 2020 and 2024, all of whom were confirmed to have ccRCC through postoperative pathological diagnosis. Among these, 85 cases had poor image quality, 64 cases had missing CTU images, and 223 cases had incomplete clinical information, leading to their exclusion from the study. 175 patients from the The Cancer Genome Atlas (TCGA) cohort were used for the external validation set. Only patients with a confirmed pathological diagnosis of ccRCC, known ISUP grading status, no prior targeted therapy or chemotherapy, no other tumors, and complete data on age, gender, and TNM staging were included. The entire patient recruitment process is illustrated in <bold>Figure <xref rid="F2" ref-type="fig">2</xref>.</bold></p></sec><sec><title>Image analysis</title><p>Thin-slice CTU images with a slice thickness of 0.625 mm were collected from patients with a confirmed diagnosis of ccRCC. Two radiologists, each with seven years of experience, were recruited to independently and systematically analyze the CTU images, without access to the clinical information. In cases where discrepancies or doubts arose, a third radiologist with 12 years of experience would review the images and make the final determination. All CTU images were then saved in DICOM format.</p></sec><sec><title>ISUP assessment</title><p>We carefully reviewed the clinical information of the patients included in the study, and their ISUP grading results were obtained from pathological diagnosis reports. We defined ISUP grades 1 and 2 as low-grade and ISUP grades 3 and 4 as high-grade for subsequent analyses<xref rid="B14" ref-type="bibr">14</xref>.</p></sec><sec><title>ROI segmentation and radiomic feature extraction</title><p>We manually segmented the lesions of clear cell carcinoma and delineated the regions of interest (ROI) using ITK-SNAP (version 3.8.0). The ROI were defined during the corticomedullary phase (CMP), and this work was carried out by two radiologists with seven years of experience. A third radiologist with 12 years of experience reviewed their work and corrected any errors. The DICOM format data was then saved as NIfTI (.nii) format. We employed Pydiomics (version 3.1.0) in Python to extract radiomic features from the aforementioned data; this package is available on GitHub<xref rid="B15" ref-type="bibr">15</xref>. The extracted radiomic features included First Order Features, Shape Features (2D), Shape Features (3D), Gray Level Co-occurrence Matrix (GLCM) Features, Gray Level Size Zone Matrix (GLSZM) Features, Gray Level Run Length Matrix (GLRLM) Features, and Gray Level Dependence Matrix (GLDM) Features. The extracted features were saved in .csv format.</p></sec><sec><title>Feature selection</title><p>We employed the Least Absolute Shrinkage and Selection Operator (LASSO) regression to perform dimensionality reduction on the extracted radiomic features, selecting important features for model construction and data analysis.</p></sec><sec><title>Model development</title><p>The participants included in the study were randomly divided into training and testing sets in a 7:3 ratio. TCGA cohort were employed for the external validation set. The features selected by LASSO were standardized using the StandardScaler function. Four models&#x02014;Logistic Regression (LR), Multilayer Perceptron (MLP), Support Vector Machine (SVM), and eXtreme Gradient Boosting (XGBoost)&#x02014;were trained to predict the ISUP grading of ccRCC patients based on their CTU image CMP. The receiver operating characteristic (ROC) curve was plotted to assess model performance. Additionally, SHapley Additive exPlanations (SHAP) were employed to explain the importance of the classification features, and an interactive force plot was created to illustrate the model's decision-making process.</p></sec><sec><title>Statistical analysis</title><p>The statistical analysis of this study was performed using Python (version 3.1.0), and all statistical tests were two-tailed, with p &#x0003c; 0.05 considered statistically significant.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Patient characteristics</title><p>The baseline information of the study population is shown in <bold>Table <xref rid="T1" ref-type="table">1</xref></bold>.</p></sec><sec><title>Radiomic feature extraction</title><p>A total of 1,218 radiomic features were extracted using the Pyradiomics package. We organized the names of the extracted radiomic features into a table, and detailed names of the radiomic features can be found in <bold><xref rid="SM0" ref-type="sec">Table S1</xref></bold>.</p></sec><sec><title>LASSO regression</title><p>A total of 1,218 radiomic features were filtered using LASSO regression, resulting in 20 features selected for model training (<bold>Figure <xref rid="F3" ref-type="fig">3</xref></bold>). The radiomic features related to the ISUP grading of ccRCC identified by LASSO regression can be found in <bold>Table <xref rid="T2" ref-type="table">2</xref></bold>.</p></sec><sec><title>The performance of machine learning models</title><p>The comparison of clinical parameters between the training set and the testing set is shown in <bold>Table <xref rid="T3" ref-type="table">3</xref></bold>, and there is no significant statistical difference between them. (p&#x0003e;0.05) In the training set, AUC for the LR model was 0.88 (95% confidence interval [CI] 0.84, 0.91), the AUC for the MLP was 0.89 (95% CI 0.86, 0.93), the AUC for the SVM was 0.86 (95% CI 0.83, 0.90), and the AUC for XGBoost was 0.96 (95% CI 0.92, 0.99) (<bold>Figure <xref rid="F4" ref-type="fig">4</xref>A</bold>). In the testing set, the AUC for LR was 0.79 (95% CI 0.73, 0.85), the AUC for MLP was 0.78 (95% CI 0.72, 0.83), the AUC for SVM was 0.78 (95% CI 0.73, 0.82), and the AUC for XGBoost was 0.80 (95% CI 0.75, 0.85) (<bold>Figure <xref rid="F4" ref-type="fig">4</xref>B</bold>). In the validation set, the AUC for LR was 0.74 (95% CI 0.68-0.79), for MLP it was 0.68 (95% CI 0.63-0.73), for SVM it was 0.67 (95% CI 0.64-0.71), and for XGBoost it was 0.78 (95% CI 0.74-0.83) (<bold>Figure <xref rid="F4" ref-type="fig">4</xref>C</bold>). XGBoost demonstrated superior performance, achieving a sensitivity of 0.99 (95% CI 0.96, 1.00) in the training set, 0.92 (95% CI 0.88-0.97) in the testing set and 0.91 (95% CI 0.86,0.95) in validation set. The performance of the four models in both the training and testing sets is summarized in <bold>Table <xref rid="T4" ref-type="table">4</xref></bold>. We employed the Delong test to statistically evaluate the AUC values obtained from the ROC curves of various models. Within the training dataset, it was observed that the XGBoost model demonstrated superior performance compared to the LR, SVM, and MLP models (p&#x0003c;0.001).</p><p>We plotted a data-class forest plot for the testing set, which visually demonstrated that XGBoost exhibited strong performance, with a narrower confidence interval compared to the other models, indicating that this model performed stably on the testing set data (<bold>Figure <xref rid="F5" ref-type="fig">5</xref></bold>).</p></sec><sec><title>SHAP analysis</title><p>We utilized the `shap_values_Explanation` function to generate a feature importance bar chart for the 20 radiomic features of the trained XGBoost model, combining the least important features for a clearer representation of each feature's importance ranking (<bold>Figure <xref rid="F6" ref-type="fig">6</xref></bold>).</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>The study pioneers a non-invasive approach to predict the ISUP grade of ccRCC by harnessing the power of artificial intelligence, with a particular emphasis on the XGBoost algorithm. It integrates radiomics feature extraction and advanced machine learning techniques to analyze CTU images. From these images, a comprehensive set of 1,218 features was extracted, and through the precision of LASSO regression, 20 key features were identified for model training. The XGBoost model's performance was rigorously evaluated across training, testing, and external validation sets, showcasing remarkable predictive capabilities, particularly with an impressive sensitivity of 0.99 in the training set. Furthermore, SHAP analysis illuminated the critical contributions of specific radiomics features to the classification process, opening new avenues for the exploration of potential biomarkers in ccRCC. This innovative method offers not only a valuable aid in clinical decision-making but also establishes a solid groundwork for the advancement of image-based cancer grading and the development of tailored treatment strategies in the future.</p><p>The WHO/ISUP grading system has been widely adopted for the pathological analysis of ccRCC. Its repeatability and strong correlation with clinical outcomes make it preferable to the Fuhrman grading system<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B17" ref-type="bibr">17</xref>.</p><p>Research has shown that the WHO/ISUP grading system correlates with outcomes and tumor biological behavior in ccRCC patients<xref rid="B18" ref-type="bibr">18</xref>. Since treatment strategies differ between high-grade and low-grade renal cancers, early differentiation and diagnosis of ccRCC can significantly benefit treatment strategy selection and patient prognosis<xref rid="B19" ref-type="bibr">19</xref>. Currently, preoperative diagnosis of ccRCC mainly relies on percutaneous renal biopsy; however, this method can introduce trauma and may not accurately identify the pathological grading of ccRCC<xref rid="B20" ref-type="bibr">20</xref>-<xref rid="B22" ref-type="bibr">22</xref>.</p><p>As a result, numerous researchers have undertaken preliminary investigations into predicting the ISUP grading of clear ccRCC using medical images. For instance, Li, Q. <italic>et al.</italic> employed a radiomic model based on multiparametric MRI to predict the ISUP grading in ccRCC patients<xref rid="B14" ref-type="bibr">14</xref>. Similarly, Chen, R. <italic>et al.</italic> demonstrated favorable outcomes using a multi-sequence MRI-based radiomic model for preoperative prediction of ISUP grading in ccRCC<xref rid="B23" ref-type="bibr">23</xref>. Additionally, Chen, Y.F. <italic>et al.</italic> found that ultrasound-based radiomics can effectively predict the ISUP grading of ccRCC<xref rid="B24" ref-type="bibr">24</xref>.</p><p>In this study, we aimed to use CTU-based radiomic technology to predict the ISUP grading of ccRCC. The machine learning models we trained showed strong performance on both the training and testing sets, with the XGBoost model demonstrating particularly stable results across both datasets. The region of interest (ROI) delineation was conducted during the CMP phase, effectively minimizing the introduction of confounding biases. Using the LASSO model, we selected 20 radiomic features for training, leveraging L1 regularization<xref rid="B25" ref-type="bibr">25</xref>. By standardizing the data prior to model training, we enhanced both the stability and accuracy of our model's performance.</p><p>Machine learning models are often referred to as "black boxes," and interpretability has long been a challenge. We addressed this issue through SHAP, which enabled us to rank the importance of the radiomic features contributing to the model.</p><p>Although the four models we trained, particularly the XGBoost model, demonstrated strong performance in both the training and testing sets, our study has several limitations. First, it was conducted within a single cohort, and the sample size was insufficient, which may restrict the generalizability of our trained model. Second, we did not have a separate external cohort for validation, which poses challenges to the model's robustness and generalizability. We aim to conduct large-sample, multicenter, prospective clinical studies to enhance the generalizability of our model and provide a non-invasive and efficient solution for predicting the nuclear grading of ccRCC.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>This study reported a novel non-invasive method for predicting the ISUP nuclear grading system of ccRCC from CTU images, providing physicians with a new strategy to enhance clinical management and improve patient outcomes.</p></sec><sec id="SM0" sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="SM1" position="float" content-type="local-data"><caption><p>Supplementary table.</p></caption><media xlink:href="jcav16p1118s1.xlsx"/></supplementary-material></sec></body><back><ack><p>We would like to thank colleagues in the Department of Urology and Radiology of RHWU for their support.</p><sec><title>Funding</title><p>This work was supported by Hubei Province Central Guiding Local Science and Technology Development Project [grant number 2022BGE232] and China Primary Health Care Foundation [grant number 025].</p></sec><sec><title>Author contributions</title><p>Conceptualization, Qingyuan Zheng and Zhiyuan Chen; Data curation, Xinmiao Ni; Formal analysis, Rui Yang, Xinmiao Ni and Jingsong Wang; Funding acquisition, Xiaodong Weng, Xiuheng Liu and Zhiyuan Chen; Investigation, Xinmiao Ni, Haonan Mei; Methodology, Panpan Jiao, Yi Lu, Yunxun Liu and Qingyuan Zheng; Project administration, Xiaodong Weng, Qingyuan Zheng, Xiuheng Liu and Zhiyuan Chen; Resources, Bin Wang and Xiaodong Weng; Software, Panpan Jiao, Bin Wang and Qingyuan Zheng; Supervision, Xiuheng Liu and Zhiyuan Chen; Validation, Rui Yang; Visualization, Bin Wang and Xinmiao Ni; Writing - original draft, Panpan Jiao and Bin Wang; Writing - review &#x00026; editing, Xiaodong Weng, Qingyuan Zheng and Zhiyuan Chen. All authors have read and agreed to the published version of the manuscript.</p></sec><sec><title>Ethics approval</title><p>The study was approved by the Clinical Research Ethics Committee, Renmin hospital of Wuhan University (protocol code WDRY2022-K077); The Clinical Research Ethics Committee, Renmin Hospital of Wuhan University (RHWU) waived the need for informed consent due to the retrospective nature of the study.</p></sec><sec sec-type="data-availability"><title>Data availability statement</title><p>The Pyradiomics package is available for free on GitHub (<ext-link xlink:href="https://github.com/AIM-Harvard/pyradiomics/" ext-link-type="uri">https://github.com/AIM-Harvard/pyradiomics/</ext-link>). For ethical reasons, the data used in this study should be provided upon request to the corresponding author.</p></sec></ack><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><name><surname>Capitanio</surname><given-names>U</given-names></name><name><surname>Montorsi</surname><given-names>F</given-names></name><article-title>Renal cancer</article-title><source>Lancet</source><year>2016</year><volume>387</volume><fpage>894</fpage><lpage>906</lpage>
<pub-id pub-id-type="pmid">26318520</pub-id>
</element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><name><surname>Sung</surname><given-names>H</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Laversanne</surname><given-names>M</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name><etal/><article-title>Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries</article-title><source>CA Cancer J Clin</source><year>2021</year><volume>71</volume><fpage>209</fpage><lpage>49</lpage>
<pub-id pub-id-type="pmid">33538338</pub-id>
</element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><name><surname>Bukavina</surname><given-names>L</given-names></name><name><surname>Bensalah</surname><given-names>K</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Carlo</surname><given-names>M</given-names></name><name><surname>Challacombe</surname><given-names>B</given-names></name><name><surname>Karam</surname><given-names>JA</given-names></name><etal/><article-title>Epidemiology of Renal Cell Carcinoma: 2022 Update</article-title><source>Eur Urol</source><year>2022</year><volume>82</volume><fpage>529</fpage><lpage>42</lpage>
<pub-id pub-id-type="pmid">36100483</pub-id>
</element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><name><surname>Moch</surname><given-names>H</given-names></name><name><surname>Cubilla</surname><given-names>AL</given-names></name><name><surname>Humphrey</surname><given-names>PA</given-names></name><name><surname>Reuter</surname><given-names>VE</given-names></name><name><surname>Ulbright</surname><given-names>TM</given-names></name><article-title>The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours</article-title><source>Eur Urol</source><year>2016</year><volume>70</volume><fpage>93</fpage><lpage>105</lpage>
<pub-id pub-id-type="pmid">26935559</pub-id>
</element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><name><surname>Montanaro</surname><given-names>L</given-names></name><name><surname>Trer&#x000e9;</surname><given-names>D</given-names></name><name><surname>Derenzini</surname><given-names>M</given-names></name><article-title>Nucleolus, ribosomes, and cancer</article-title><source>Am J Pathol</source><year>2008</year><volume>173</volume><fpage>301</fpage><lpage>10</lpage>
<pub-id pub-id-type="pmid">18583314</pub-id>
</element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><name><surname>Derenzini</surname><given-names>M</given-names></name><name><surname>Montanaro</surname><given-names>L</given-names></name><name><surname>Trer&#x000e9;</surname><given-names>D</given-names></name><article-title>What the nucleolus says to a tumour pathologist</article-title><source>Histopathology</source><year>2009</year><volume>54</volume><fpage>753</fpage><lpage>62</lpage>
<pub-id pub-id-type="pmid">19178588</pub-id>
</element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><name><surname>Rashid</surname><given-names>F</given-names></name><name><surname>Ul Haque</surname><given-names>A</given-names></name><article-title>Frequencies of different nuclear morphological features in prostate adenocarcinoma</article-title><source>Ann Diagn Pathol</source><year>2011</year><volume>15</volume><fpage>414</fpage><lpage>21</lpage>
<pub-id pub-id-type="pmid">21849255</pub-id>
</element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><name><surname>Delahunt</surname><given-names>B</given-names></name><name><surname>Cheville</surname><given-names>JC</given-names></name><name><surname>Martignoni</surname><given-names>G</given-names></name><name><surname>Humphrey</surname><given-names>PA</given-names></name><name><surname>Magi-Galluzzi</surname><given-names>C</given-names></name><name><surname>McKenney</surname><given-names>J</given-names></name><etal/><article-title>The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters</article-title><source>Am J Surg Pathol</source><year>2013</year><volume>37</volume><fpage>1490</fpage><lpage>504</lpage>
<pub-id pub-id-type="pmid">24025520</pub-id>
</element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><name><surname>Shuch</surname><given-names>B</given-names></name><name><surname>Bratslavsky</surname><given-names>G</given-names></name><name><surname>Linehan</surname><given-names>WM</given-names></name><name><surname>Srinivasan</surname><given-names>R</given-names></name><article-title>Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies</article-title><source>Oncologist</source><year>2012</year><volume>17</volume><fpage>46</fpage><lpage>54</lpage>
<pub-id pub-id-type="pmid">22234634</pub-id>
</element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><name><surname>Fuhrman</surname><given-names>SA</given-names></name><name><surname>Lasky</surname><given-names>LC</given-names></name><name><surname>Limas</surname><given-names>C</given-names></name><article-title>Prognostic significance of morphologic parameters in renal cell carcinoma</article-title><source>Am J Surg Pathol</source><year>1982</year><volume>6</volume><fpage>655</fpage><lpage>63</lpage>
<pub-id pub-id-type="pmid">7180965</pub-id>
</element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><name><surname>Yeh</surname><given-names>FC</given-names></name><name><surname>Parwani</surname><given-names>AV</given-names></name><name><surname>Pantanowitz</surname><given-names>L</given-names></name><name><surname>Ho</surname><given-names>C</given-names></name><article-title>Automated grading of renal cell carcinoma using whole slide imaging</article-title><source>J Pathol Inform</source><year>2014</year><volume>5</volume><fpage>23</fpage>
<pub-id pub-id-type="pmid">25191622</pub-id>
</element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><name><surname>Pan</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Jin</surname><given-names>P</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name><name><surname>Cai</surname><given-names>P</given-names></name><etal/><article-title>Prediction of Fuhrman grade of renal clear cell carcinoma by multimodal MRI radiomics: a retrospective study</article-title><source>Clin Radiol</source><year>2024</year><volume>79</volume><fpage>e273</fpage><lpage>e81</lpage>
<pub-id pub-id-type="pmid">38065776</pub-id>
</element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Ma</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><etal/><article-title>Prediction of Fuhrman nuclear grade for clear cell renal carcinoma by a multi-information fusion model that incorporates CT-based features of tumor and serum tumor associated material</article-title><source>J Cancer Res Clin Oncol</source><year>2023</year><volume>149</volume><fpage>15855</fpage><lpage>65</lpage>
<pub-id pub-id-type="pmid">37672076</pub-id>
</element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>YJ</given-names></name><name><surname>Dong</surname><given-names>D</given-names></name><name><surname>Bai</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>QB</given-names></name><name><surname>Guo</surname><given-names>AT</given-names></name><etal/><article-title>Multiparametric MRI Radiomic Model for Preoperative Predicting WHO/ISUP Nuclear Grade of Clear Cell Renal Cell Carcinoma</article-title><source>J Magn Reson Imaging</source><year>2020</year><volume>52</volume><fpage>1557</fpage><lpage>66</lpage>
<pub-id pub-id-type="pmid">32462799</pub-id>
</element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="other">
<comment>Open-source python package for the extraction of Radiomics features from 2D and 3D images and binary masks. 2023</comment>
</element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><name><surname>Delahunt</surname><given-names>B</given-names></name><name><surname>Eble</surname><given-names>JN</given-names></name><name><surname>Egevad</surname><given-names>L</given-names></name><name><surname>Samaratunga</surname><given-names>H</given-names></name><article-title>Grading of renal cell carcinoma</article-title><source>Histopathology</source><year>2019</year><volume>74</volume><fpage>4</fpage><lpage>17</lpage>
<pub-id pub-id-type="pmid">30565310</pub-id>
</element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><name><surname>Warren</surname><given-names>AY</given-names></name><name><surname>Harrison</surname><given-names>D</given-names></name><article-title>WHO/ISUP classification, grading and pathological staging of renal cell carcinoma: standards and controversies</article-title><source>World J Urol</source><year>2018</year><volume>36</volume><fpage>1913</fpage><lpage>26</lpage>
<pub-id pub-id-type="pmid">30123932</pub-id>
</element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><name><surname>Frank</surname><given-names>I</given-names></name><name><surname>Blute</surname><given-names>ML</given-names></name><name><surname>Cheville</surname><given-names>JC</given-names></name><name><surname>Lohse</surname><given-names>CM</given-names></name><name><surname>Weaver</surname><given-names>AL</given-names></name><name><surname>Zincke</surname><given-names>H</given-names></name><article-title>An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score</article-title><source>J Urol</source><year>2002</year><volume>168</volume><fpage>2395</fpage><lpage>400</lpage>
<pub-id pub-id-type="pmid">12441925</pub-id>
</element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><name><surname>Ljungberg</surname><given-names>B</given-names></name><name><surname>Albiges</surname><given-names>L</given-names></name><name><surname>Abu-Ghanem</surname><given-names>Y</given-names></name><name><surname>Bensalah</surname><given-names>K</given-names></name><name><surname>Dabestani</surname><given-names>S</given-names></name><name><surname>Fern&#x000e1;ndez-Pello</surname><given-names>S</given-names></name><etal/><article-title>European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update</article-title><source>Eur Urol</source><year>2019</year><volume>75</volume><fpage>799</fpage><lpage>810</lpage>
<pub-id pub-id-type="pmid">30803729</pub-id>
</element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><name><surname>Blumenfeld</surname><given-names>AJ</given-names></name><name><surname>Guru</surname><given-names>K</given-names></name><name><surname>Fuchs</surname><given-names>GJ</given-names></name><name><surname>Kim</surname><given-names>HL</given-names></name><article-title>Percutaneous biopsy of renal cell carcinoma underestimates nuclear grade</article-title><source>Urology</source><year>2010</year><volume>76</volume><fpage>610</fpage><lpage>3</lpage>
<pub-id pub-id-type="pmid">20163843</pub-id>
</element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><name><surname>Ficarra</surname><given-names>V</given-names></name><name><surname>Brunelli</surname><given-names>M</given-names></name><name><surname>Novara</surname><given-names>G</given-names></name><name><surname>D'Elia</surname><given-names>C</given-names></name><name><surname>Segala</surname><given-names>D</given-names></name><name><surname>Gardiman</surname><given-names>M</given-names></name><etal/><article-title>Accuracy of on-bench biopsies in the evaluation of the histological subtype, grade, and necrosis of renal tumours</article-title><source>Pathology</source><year>2011</year><volume>43</volume><fpage>149</fpage><lpage>55</lpage>
<pub-id pub-id-type="pmid">21233677</pub-id>
</element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><name><surname>Marconi</surname><given-names>L</given-names></name><name><surname>Dabestani</surname><given-names>S</given-names></name><name><surname>Lam</surname><given-names>TB</given-names></name><name><surname>Hofmann</surname><given-names>F</given-names></name><name><surname>Stewart</surname><given-names>F</given-names></name><name><surname>Norrie</surname><given-names>J</given-names></name><etal/><article-title>Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy</article-title><source>Eur Urol</source><year>2016</year><volume>69</volume><fpage>660</fpage><lpage>73</lpage>
<pub-id pub-id-type="pmid">26323946</pub-id>
</element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Su</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Tan</surname><given-names>Y</given-names></name><article-title>Multi-sequence MRI-based radiomics model to preoperatively predict the WHO/ISUP grade of clear Cell Renal Cell Carcinoma: a two-center study</article-title><source>BMC Cancer</source><year>2024</year><volume>24</volume><fpage>1176</fpage>
<pub-id pub-id-type="pmid">39333970</pub-id>
</element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><name><surname>Chen</surname><given-names>YF</given-names></name><name><surname>Fu</surname><given-names>F</given-names></name><name><surname>Zhuang</surname><given-names>JJ</given-names></name><name><surname>Zheng</surname><given-names>WT</given-names></name><name><surname>Zhu</surname><given-names>YF</given-names></name><name><surname>Lian</surname><given-names>GT</given-names></name><etal/><article-title>Ultrasound-Based Radiomics for Predicting the WHO/ISUP Grading of Clear-Cell Renal Cell Carcinoma</article-title><source>Ultrasound Med Biol</source><year>2024</year><volume>50</volume><fpage>1619</fpage><lpage>27</lpage>
<pub-id pub-id-type="pmid">39097493</pub-id>
</element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Kwan</surname><given-names>PW</given-names></name><name><surname>Shi</surname><given-names>D</given-names></name><article-title>Sparse kernel learning with LASSO and Bayesian inference algorithm</article-title><source>Neural Netw</source><year>2010</year><volume>23</volume><fpage>257</fpage><lpage>64</lpage>
<pub-id pub-id-type="pmid">19604671</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="F1"><label>Figure 1</label><caption><p>The entire workflow of the study. <bold>(A)</bold> Collect images of ccRCC; <bold>(B)</bold> ROI was determined and image omics feature extraction was performed; <bold>(C)</bold> Radiomics features screening; <bold>(D)</bold> Train the model and demonstrate its interpretability.</p></caption><graphic xlink:href="jcav16p1118g001" position="float"/></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p>Recruitment process of RHWU cohort.</p></caption><graphic xlink:href="jcav16p1118g002" position="float"/></fig><fig position="float" id="F3"><label>Figure 3</label><caption><p><bold> (A)</bold> LASSO Regression Coefficient Path Plot.<bold> (B)</bold> LASSO Regression Cross-Validation Curve.</p></caption><graphic xlink:href="jcav16p1118g003" position="float"/><graphic xlink:href="jcav16p1118g004" position="float"/></fig><fig position="float" id="F4"><label>Figure 4</label><caption><p><bold> (A)</bold> The ROC curves for the four models&#x02014;LR, MLP, SVM, and XGBoost&#x02014;in the training set.<bold> (B)</bold> The ROC curves for the four models&#x02014;LR, MLP, SVM, and XGBoost&#x02014;in the testing set. <bold>(C)</bold> The ROC curves for the four models&#x02014;LR, MLP, SVM, and XGBoost&#x02014;in the validation set.</p></caption><graphic xlink:href="jcav16p1118g005" position="float"/><graphic xlink:href="jcav16p1118g006" position="float"/><graphic xlink:href="jcav16p1118g007" position="float"/></fig><fig position="float" id="F5"><label>Figure 5</label><caption><p>AUC Scores with 95% Confidence intervals for different models.</p></caption><graphic xlink:href="jcav16p1118g008" position="float"/></fig><fig position="float" id="F6"><label>Figure 6</label><caption><p>Feature Importance Bar Chart Generated by SHAP.</p></caption><graphic xlink:href="jcav16p1118g009" position="float"/></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Clinical and pathological characteristics of ccRCC patients included in the RHWU and TCGA cohort.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Characteristics</th><th rowspan="1" colspan="1">RHWU (<italic>N</italic> = 328)</th><th rowspan="1" colspan="1">TCGA (<italic>N =</italic> 175)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age (years)</td><td rowspan="1" colspan="1">59 (25,84)</td><td rowspan="1" colspan="1">59 (26,88)</td></tr><tr><td rowspan="1" colspan="1">Gender</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">124 (37.8%)</td><td rowspan="1" colspan="1">64 (36.5%)</td></tr><tr><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">204 (62.2%)</td><td rowspan="1" colspan="1">111 (63.5%)</td></tr><tr><td rowspan="1" colspan="1">pT stage</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">pT1</td><td rowspan="1" colspan="1">224 (68.3%)</td><td rowspan="1" colspan="1">92 (52.5%)</td></tr><tr><td rowspan="1" colspan="1">pT2</td><td rowspan="1" colspan="1">40 (12.1%)</td><td rowspan="1" colspan="1">19 (10.9%)</td></tr><tr><td rowspan="1" colspan="1">pT3</td><td rowspan="1" colspan="1">51 (15.6%)</td><td rowspan="1" colspan="1">61 (34.9%)</td></tr><tr><td rowspan="1" colspan="1">pT4</td><td rowspan="1" colspan="1">13 (4.0%)</td><td rowspan="1" colspan="1">3 (1.7%)</td></tr><tr><td rowspan="1" colspan="1">pN stage</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">pN0</td><td rowspan="1" colspan="1">326 (99.4%)</td><td rowspan="1" colspan="1">74 (42.3%)</td></tr><tr><td rowspan="1" colspan="1">pN1</td><td rowspan="1" colspan="1">2 (0.6%)</td><td rowspan="1" colspan="1">3 (1.7%)</td></tr><tr><td rowspan="1" colspan="1">pNx</td><td rowspan="1" colspan="1">0 (0%)</td><td rowspan="1" colspan="1">98 (56.0%)</td></tr><tr><td rowspan="1" colspan="1">pM stage</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">pM0</td><td rowspan="1" colspan="1">326 (99.4%)</td><td rowspan="1" colspan="1">144 (82.3%)</td></tr><tr><td rowspan="1" colspan="1">pM1</td><td rowspan="1" colspan="1">2 (0.6%)</td><td rowspan="1" colspan="1">25 (14.3%)</td></tr><tr><td rowspan="1" colspan="1">pMx</td><td rowspan="1" colspan="1">0 (0%)</td><td rowspan="1" colspan="1">6 (3.4%)</td></tr><tr><td rowspan="1" colspan="1">pTNM stage</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Stage I</td><td rowspan="1" colspan="1">225 (68.6%)</td><td rowspan="1" colspan="1">89 (50.9%)</td></tr><tr><td rowspan="1" colspan="1">Stage II</td><td rowspan="1" colspan="1">39 (11.9%)</td><td rowspan="1" colspan="1">15 (8.6%)</td></tr><tr><td rowspan="1" colspan="1">Stage III</td><td rowspan="1" colspan="1">51 (15.5%)</td><td rowspan="1" colspan="1">44 (25.1%)</td></tr><tr><td rowspan="1" colspan="1">Stage IV</td><td rowspan="1" colspan="1">13 (4.0%)</td><td rowspan="1" colspan="1">27 (15.4%)</td></tr><tr><td rowspan="1" colspan="1">ISUP</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Low</td><td rowspan="1" colspan="1">242 (73.8%)</td><td rowspan="1" colspan="1">71 (40.1%)</td></tr><tr><td rowspan="1" colspan="1">High</td><td rowspan="1" colspan="1">86 (26.2%)</td><td rowspan="1" colspan="1">104 (59.9%)</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Radiomics features associated with ISUP grading selected by LASSO regression.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Signature</th><th rowspan="1" colspan="1">Coefficients</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">original_shape_Maximum2DDiameterColumn</td><td rowspan="1" colspan="1">0.00222852737199394</td></tr><tr><td rowspan="1" colspan="1">original_glcm_Idn</td><td rowspan="1" colspan="1">10.1546499325103</td></tr><tr><td rowspan="1" colspan="1">original_glrlm_ShortRunEmphasis</td><td rowspan="1" colspan="1">-0.132918290548955</td></tr><tr><td rowspan="1" colspan="1">original_glszm_GrayLevelNonUniformity</td><td rowspan="1" colspan="1">0.000411156981777663</td></tr><tr><td rowspan="1" colspan="1">log-sigma-3-0-mm-3D_firstorder_Skewness</td><td rowspan="1" colspan="1">-0.00178145972896154</td></tr><tr><td rowspan="1" colspan="1">log-sigma-3-0-mm-3D_glszm_GrayLevelNonUniformity</td><td rowspan="1" colspan="1">0.000879435041237894</td></tr><tr><td rowspan="1" colspan="1">log-sigma-5-0-mm-3D_gldm_GrayLevelNonUniformity</td><td rowspan="1" colspan="1">8.17007542499914e-07</td></tr><tr><td rowspan="1" colspan="1">wavelet-LLH_firstorder_Maximum</td><td rowspan="1" colspan="1">0.00113570868341896</td></tr><tr><td rowspan="1" colspan="1">wavelet-LLH_glcm_JointAverage</td><td rowspan="1" colspan="1">0.0060224563563358</td></tr><tr><td rowspan="1" colspan="1">wavelet-LLH_glszm_SmallAreaEmphasis</td><td rowspan="1" colspan="1">1.434207623494</td></tr><tr><td rowspan="1" colspan="1">wavelet-LHL_glcm_Idn</td><td rowspan="1" colspan="1">2.08239378405782</td></tr><tr><td rowspan="1" colspan="1">wavelet-LHL_glrlm_LongRunEmphasis</td><td rowspan="1" colspan="1">0.171694741441655</td></tr><tr><td rowspan="1" colspan="1">wavelet-LHL_glszm_LargeAreaLowGrayLevelEmphasis</td><td rowspan="1" colspan="1">4.61024679022084e-07</td></tr><tr><td rowspan="1" colspan="1">wavelet-LHH_glszm_SizeZoneNonUniformityNormalized</td><td rowspan="1" colspan="1">0.87375601873421</td></tr><tr><td rowspan="1" colspan="1">wavelet-HLL_glszm_LargeAreaLowGrayLevelEmphasis</td><td rowspan="1" colspan="1">6.48325519507287e-07</td></tr><tr><td rowspan="1" colspan="1">wavelet-HLH_glcm_JointAverage</td><td rowspan="1" colspan="1">0.0665272864500797</td></tr><tr><td rowspan="1" colspan="1">wavelet-HLH_glrlm_ShortRunHighGrayLevelEmphasis</td><td rowspan="1" colspan="1">0.0167593670054085</td></tr><tr><td rowspan="1" colspan="1">wavelet-HHL_glrlm_LongRunHighGrayLevelEmphasis</td><td rowspan="1" colspan="1">-0.000162138701876053</td></tr><tr><td rowspan="1" colspan="1">wavelet-HHL_glrlm_LongRunLowGrayLevelEmphasis</td><td rowspan="1" colspan="1">0.10348165095976</td></tr><tr><td rowspan="1" colspan="1">wavelet-LLL_gldm_LargeDependenceLowGrayLevelEmphasis</td><td rowspan="1" colspan="1">0.0486078683527515</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Comparison of clinical parameters between training set and testing set.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Variable</th><th rowspan="1" colspan="1">Overall, N = 328<sup>1</sup></th><th rowspan="1" colspan="1">Training set, N = 230<sup>1</sup></th><th rowspan="1" colspan="1">Testing set, N = 98<sup>1</sup></th><th rowspan="1" colspan="1">p-value<sup>2</sup></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Gender</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.084</td></tr><tr><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">124 (38%)</td><td rowspan="1" colspan="1">80 (35%)</td><td rowspan="1" colspan="1">44 (45%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">204 (62%)</td><td rowspan="1" colspan="1">150 (65%)</td><td rowspan="1" colspan="1">54 (55%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Age</td><td rowspan="1" colspan="1">59 (52, 66)</td><td rowspan="1" colspan="1">58 (51, 66)</td><td rowspan="1" colspan="1">62 (55, 66)</td><td rowspan="1" colspan="1">0.051</td></tr><tr><td rowspan="1" colspan="1">pTNM stage</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.081</td></tr><tr><td rowspan="1" colspan="1">I</td><td rowspan="1" colspan="1">225 (69%)</td><td rowspan="1" colspan="1">166 (72%)</td><td rowspan="1" colspan="1">59 (60%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">II</td><td rowspan="1" colspan="1">39 (12%)</td><td rowspan="1" colspan="1">22 (9.6%)</td><td rowspan="1" colspan="1">17 (17%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">III</td><td rowspan="1" colspan="1">51 (16%)</td><td rowspan="1" colspan="1">35 (15%)</td><td rowspan="1" colspan="1">16 (16%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">IV</td><td rowspan="1" colspan="1">13 (4.0%)</td><td rowspan="1" colspan="1">7 (3.0%)</td><td rowspan="1" colspan="1">6 (6.1%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">ISUP Grade</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">0.15</td></tr><tr><td rowspan="1" colspan="1">Low-grade</td><td rowspan="1" colspan="1">242 (74%)</td><td rowspan="1" colspan="1">175 (76%)</td><td rowspan="1" colspan="1">67 (68%)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">High-grade</td><td rowspan="1" colspan="1">86 (26%)</td><td rowspan="1" colspan="1">55 (24%)</td><td rowspan="1" colspan="1">31 (32%)</td><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup>Median (IQR) or Frequency (%)</p><p><sup>2</sup>Pearson's Chi-squared test; Wilcoxon rank sum test; Fisher's exact test</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Model performance summary.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Data Set</th><th rowspan="1" colspan="1">Model</th><th rowspan="1" colspan="1">AUC (95%CI)</th><th rowspan="1" colspan="1">Sensitivity (95%CI)</th><th rowspan="1" colspan="1">Accuracy (95%CI)</th></tr></thead><tbody><tr><td rowspan="4" colspan="1">Training</td><td rowspan="1" colspan="1">LR</td><td rowspan="1" colspan="1">0.88 (0.84,0.91)</td><td rowspan="1" colspan="1">0.95 (0.92,0.98)</td><td rowspan="1" colspan="1">0.87 (0.81,0.92)</td></tr><tr><td rowspan="1" colspan="1">MLP</td><td rowspan="1" colspan="1">0.89 (0.86,0.93)</td><td rowspan="1" colspan="1">0.95 (0.91,0.98)</td><td rowspan="1" colspan="1">0.86 (0.83,0.90)</td></tr><tr><td rowspan="1" colspan="1">SVM</td><td rowspan="1" colspan="1">0.86 (0.83,0.90)</td><td rowspan="1" colspan="1">0.98 (0.94,1.00)</td><td rowspan="1" colspan="1">0.87 (0.82,0.91)</td></tr><tr><td rowspan="1" colspan="1">XGBoost</td><td rowspan="1" colspan="1">0.96 (0.92,0.99)</td><td rowspan="1" colspan="1">0.99 (0.96,1.00)</td><td rowspan="1" colspan="1">0.93 (0.88,0.97)</td></tr><tr><td rowspan="4" colspan="1">Testing</td><td rowspan="1" colspan="1">LR</td><td rowspan="1" colspan="1">0.79 (0.73,0.85)</td><td rowspan="1" colspan="1">0.89 (0.83,0.94)</td><td rowspan="1" colspan="1">0.77 (0.72,0.81)</td></tr><tr><td rowspan="1" colspan="1">MLP</td><td rowspan="1" colspan="1">0.78 (0.72,0.83)</td><td rowspan="1" colspan="1">0.89 (0.85,0.92)</td><td rowspan="1" colspan="1">0.79 (0.75,0.82)</td></tr><tr><td rowspan="1" colspan="1">SVM</td><td rowspan="1" colspan="1">0.78 (0.73,0.82)</td><td rowspan="1" colspan="1">0.96 (0.93,0,98)</td><td rowspan="1" colspan="1">0.77 (0.73,0.81)</td></tr><tr><td rowspan="1" colspan="1">XGBoost</td><td rowspan="1" colspan="1">0.80 (0.75,0.85)</td><td rowspan="1" colspan="1">0.92 (0.88,0.97)</td><td rowspan="1" colspan="1">0.80 (0.74,0.87)</td></tr><tr><td rowspan="4" colspan="1">Validation</td><td rowspan="1" colspan="1">LR</td><td rowspan="1" colspan="1">0.74 (0.68,0.79)</td><td rowspan="1" colspan="1">0.85 (0.81,0.88)</td><td rowspan="1" colspan="1">0.80 (0.75,0.84)</td></tr><tr><td rowspan="1" colspan="1">MLP</td><td rowspan="1" colspan="1">0.68 (0.63,0.73)</td><td rowspan="1" colspan="1">0.73 (0.68,0.79)</td><td rowspan="1" colspan="1">0.78 (0.72,0.84)</td></tr><tr><td rowspan="1" colspan="1">SVM</td><td rowspan="1" colspan="1">0.67 (0.64,0.71)</td><td rowspan="1" colspan="1">0.79 (0.76,0,83)</td><td rowspan="1" colspan="1">0.74 (0.69,0.78)</td></tr><tr><td rowspan="1" colspan="1">XGBoost</td><td rowspan="1" colspan="1">0.78 (0.74,0.83)</td><td rowspan="1" colspan="1">0.91 (0.86,0.95)</td><td rowspan="1" colspan="1">0.86 (0.82,0.89)</td></tr></tbody></table></table-wrap></floats-group></article>